Facilitated By

San Antonio Medical Foundation

News

  • Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines ... - BioSpace

    DAN-222 Phase 1 dose-escalation data at San Antonio Breast Cancer Symposium ... Dantari, Inc. is a clinical-stage biotechnology company developing ...

  • Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset ...

    ... One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS) ...

  • Dantari emerges with a new way to make cancer drug conjugates - BioPharma Dive

    Dive Brief // Emerging biotech ... set to be presented Thursday at the San Antonio Breast Cancer Symposium, ... STORYLINE // Emerging biotech.

  • Longer follow-up supports benefit of abemaciclib for high-risk breast cancer - Healio

    SAN ANTONIO — The benefit of adding abemaciclib to adjuvant endocrine therapy for certain patients with high-risk breast cancer deepened with time ...

  • Metastasis 'Doorway' May Lead to Racial Disparities in Breast Cancer | MedPage Today

    SAN ANTONIO -- Black patients with certain types of breast cancer treated with chemotherapy had increased concentrations of a cellular complex ...